Argenx CIDP Data Set To Attract Big Pharma Suitors

Pipeline-In-A-Product Vyvgart Sweeps Through Another Phase III

The very positive Vyvgart ADHERE data in chronic inflammatory demyelinating polyneuropathy, the recent approval for the subcutaneous version for generalized myasthenia gravis and the drug's already strong sales mean that Argenx will again be at the top of the M&A targets tree.

Lions
On the prowl: Pharma's big cats are looking for assets • Source: Shutterstock

argenx N.V.'s position as one of the crown jewels of the European biotech sector, and a rumored takeover target for big pharma, has been enhanced by positive late-stage data on its pipeline-in-a-product Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP).

The Belgian-Dutch group has unveiled topline results from the Phase III ADHERE study evaluating the subcutaneous version of the drug,...

More from Strategy

More from Business

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.